Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Ani Pharmaceuticals (ANIP) over the last 14 years, with Q3 2025 value amounting to $27.0 million.

  • Ani Pharmaceuticals' Change in Receivables rose 41956.62% to $27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.2 million, marking a year-over-year increase of 36517.06%. This contributed to the annual value of $21.1 million for FY2024, which is 72777.61% up from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Change in Receivables is $27.0 million, which was up 41956.62% from $5.5 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Change in Receivables' 5-year high stood at $27.0 million during Q3 2025, with a 5-year trough of -$16.8 million in Q4 2023.
  • For the 5-year period, Ani Pharmaceuticals' Change in Receivables averaged around $4.8 million, with its median value being $3.1 million (2022).
  • Its Change in Receivables has fluctuated over the past 5 years, first skyrocketed by 233329.02% in 2022, then tumbled by 25366.13% in 2024.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Change in Receivables stood at -$5.4 million in 2021, then surged by 565.38% to $25.0 million in 2022, then tumbled by 167.04% to -$16.8 million in 2023, then surged by 252.2% to $25.5 million in 2024, then grew by 5.69% to $27.0 million in 2025.
  • Its Change in Receivables stands at $27.0 million for Q3 2025, versus $5.5 million for Q2 2025 and -$1.8 million for Q1 2025.